Hepsera Articles
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
26 November 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
Gilead publishes more Viread data in NEJM
15 December 2008
Viread suppresses HBV through 96 weeks
10 November 2008
Gilead up almost 30% on HIV franchise
27 October 2008
China's hep B market $800M by 2012
8 September 2008
US FDA approves Gilead's Viread chronic HBV infection
18 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
B-MS' Baraclude fares well vs Hepsera
5 May 2008
Strong Ph III data for Gilead's Viread
5 May 2008
Gilead record sales push revenue up 22%
28 April 2008
Better 48-week efficacy with Viread vs Hepsera
21 November 2007
Gilead's 3rd-qtr 2007 revenue jumps 41%
29 October 2007
Gilead's Viread shows promise in HBV trial
18 June 2007
Gilead's Viread "non-inferior" to Hepsera
11 June 2007
Gilead's 1st-qtr 2007 net income sky-rockets 55%
30 April 2007
13 new drugs added to Japan's NHI list
18 September 2006
Gilead to donate $1.1M a year to Czech IOCB
24 July 2006
Gilead's 1st-qtr sales reach $692.9M, up 61%
15 May 2006
Strong data for Metabasis' HBV drug
27 March 2006
Gilead reports $2B revenue in 2005, up 53%
6 February 2006
Gilead's 2nd-qtr revenues up 55%
1 August 2005
Truvada lifts 1st qtr for Gilead Sciences
25 April 2005
Massive growth potential of China
6 September 2004
Metabasis initiates Ph II remofovir trial
9 August 2004
Gilead 1st-qtr 2004 revenues rocket 87%
3 May 2004
Gilead soars on strong HIV drug sales
10 November 2003
NICE plans six new pharma guidelines for NHS in England/Wales
20 October 2003
Gilead's Hepsera for hep B OKed in Europe
17 March 2003
Stock Commentary - New York
12 August 2002
GSK licenses Gilead's adefovir
6 May 2002
Gilead files hep B drug adefovir in EU/USA
1 April 2002
Antivirals promise major rewards in hep B virus therapy: study.
21 January 2002
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
Gilead's adefovir clears second Ph III trial
20 September 2001
Gilead's adefovir works in HIV/HBV co-infection
31 August 2001
Gilead's adefovir to be filed for HBV in 2002
26 June 2001
Stock Commentary - New York
3 May 2001
Gilead's adefovir effective in HBV
24 April 2001
Stock Commentary New York
16 December 1999
Gilead calls halt to Preveon in HIV
6 December 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
Stock Commentary New York
11 March 1999
Gilead ready to submit Preveon NDA
4 March 1999
Gilead Sciences to merge with NeXstar
2 March 1999
Stock Commentary New York
25 February 1999
Adefovir Shows High Potency In Hepatitis B
11 November 1998
Gilead's Preveon, Expanded Access
11 December 1997
Progress With Gilead Sciences' Antivirals
3 February 1997
Gilead Sciences Begins Ph III With HIV Drug
27 January 1997
New Hepatitis Treatments Highlighted At ICAAC
7 October 1996
Gilead AIDS Treatment In Pivotal Testing
10 June 1996
Showing 1-62 of 62 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
